Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)
Latest Information Update: 14 Mar 2025
Price :
$35 *
At a glance
- Drugs Empagliflozin (Primary) ; Finerenone (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONFIRMATION-HF
- 11 Mar 2025 Planned End Date changed from 1 Aug 2025 to 1 Aug 2026.
- 11 Mar 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Jul 2026.
- 22 Jul 2024 Status changed from not yet recruiting to recruiting.